2 reports of this reaction
1.4% of all CAMPHOR, MENTHOL, METHYL SALICYLATE reports
#19 most reported adverse reaction
NEOPLASM MALIGNANT is the #19 most commonly reported adverse reaction for CAMPHOR, MENTHOL, METHYL SALICYLATE, manufactured by Hisamitsu America, Inc.. There are 2 FDA adverse event reports linking CAMPHOR, MENTHOL, METHYL SALICYLATE to NEOPLASM MALIGNANT. This represents approximately 1.4% of all 141 adverse event reports for this drug.
Patients taking CAMPHOR, MENTHOL, METHYL SALICYLATE who experience neoplasm malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM MALIGNANT is a less commonly reported adverse event for CAMPHOR, MENTHOL, METHYL SALICYLATE, but still significant enough to appear in the safety profile.
In addition to neoplasm malignant, the following adverse reactions have been reported for CAMPHOR, MENTHOL, METHYL SALICYLATE:
The following drugs have also been linked to neoplasm malignant in FDA adverse event reports:
NEOPLASM MALIGNANT has been reported as an adverse event in 2 FDA reports for CAMPHOR, MENTHOL, METHYL SALICYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM MALIGNANT accounts for approximately 1.4% of all adverse event reports for CAMPHOR, MENTHOL, METHYL SALICYLATE, making it a notable side effect.
If you experience neoplasm malignant while taking CAMPHOR, MENTHOL, METHYL SALICYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.